Literature DB >> 22987977

Personalized surgical therapy.

J-C Tonn1, N Thon, O Schnell, F W Kreth.   

Abstract

Gliomas are more or less diffuse tumours with the ability to infiltrate surrounding functional brain tissue. Thus, curative surgical treatment generally cannot be achieved. Despite these limitations, open tumour resection represents one of the mainstays in glioma treatment settings. Beyond tissue sampling for accurate histological and molecular genetic evaluation, decompressive effects in the case of space occupying tumours and oncologically relevant cytoreductive effects of microsurgery have been reported in selected patients with glioma of different grades. This paper provides practical considerations in order to integrate the concept of a personalized surgical therapy into the prognostic network of low- and high-grade gliomas, covering both microsurgery and stereotactic biopsy techniques.

Entities:  

Mesh:

Year:  2012        PMID: 22987977     DOI: 10.1093/annonc/mds363

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

Review 1.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

2.  Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas.

Authors:  Juliana Watson; Alexander Romagna; Hendrik Ballhausen; Maximilian Niyazi; Stefanie Lietke; Sebastian Siller; Claus Belka; Niklas Thon; Silke Birgit Nachbichler
Journal:  Radiat Oncol       Date:  2020-12-09       Impact factor: 3.481

3.  COMMD4 is a novel prognostic biomarker and relates to potential drug resistance mechanism in glioma.

Authors:  Zongheng Liu; Long Peng; Yidan Sun; Zhichao Lu; Bing Wu; Weichen Wang; Xiaomei Zhang; Haiyan Hao; Peipei Gong
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

Review 4.  Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

Authors:  Niklas Thon; Simone Kreth; Friedrich-Wilhelm Kreth
Journal:  Onco Targets Ther       Date:  2013-09-27       Impact factor: 4.147

5.  Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.

Authors:  Leor Zach; David Guez; David Last; Dianne Daniels; Yuval Grober; Ouzi Nissim; Chen Hoffmann; Dvora Nass; Alisa Talianski; Roberto Spiegelmann; Zvi R Cohen; Yael Mardor
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches.

Authors:  Adrien Holzgreve; Matthias Brendel; Song Gu; Janette Carlsen; Erik Mille; Guido Böning; Giorgia Mastrella; Marcus Unterrainer; Franz J Gildehaus; Axel Rominger; Peter Bartenstein; Roland E Kälin; Rainer Glass; Nathalie L Albert
Journal:  Front Neurosci       Date:  2016-06-14       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.